Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone

Cancer

Volumn 117, Issue 16, 2011, Pages 3650-3657

  Holmes, Phoebe ^a   Lloyd, Joshua ^a   Chervoneva, Inna ^b   Pequinot, Edward ^b   Cornfield, Dennis B ^c   Schwartz, Gordon F ^a   Allen, Kathleen G ^d   Palazzo, Juan P ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c LEHIGH VALLEY HOSPITAL   (United States)

^d Morton Plant Hospital   (United States)

Author keywords

breast conservation surgery; ductal carcinoma in situ; prognostic markers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BREAST NECROSIS; CANCER GRADING; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80051513712     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25942     Document Type: Article

References (34)

1. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002; 94: 1546-1554. (Pubitemid 35277278)
2. Erbas B, Provenzano E, Armes J, Gertig D,. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006; 97: 135-144.
3. Leonard GD, Swain SM,. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004; 96: 906-920. (Pubitemid 38868137)
4. Sanders ME, Schuyler PA, Dupont WD, et al. The natural history of low- grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005; 103: 2481-2484. (Pubitemid 40800525)
5. Baxter N, Virnig B, Durham S, et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004; 96: 443-448. (Pubitemid 38443647)
6. Warren J, Weaver D, Bocklage T, et al. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS. Cancer. 2005; 104: 1840-1848. (Pubitemid 41513166)
7. Wong J, Kaelin C, Troyan S, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006; 24: 1031-1036. (Pubitemid 46638798)
8. Ernster VL, Barclay J, Kerlikowske K, et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology and End Results program. Arch Intern Med. 2000; 160: 953-958. (Pubitemid 30191923)
9. Altintas S, Lambein K, Huizing M, et al. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Breast J. 2009; 15: 120-132.
10. Balleine R, Webster L, Davis S, et al. Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res. 2008; 14: 8244-8252.
11. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: finding from National Surgical Adjuvant Breast and Vowel Project B-17. J Clin Oncol. 1998; 16: 441-452. (Pubitemid 28135585)
12. MacAusland S, Hepel J, Chong F, et al. An attempt to independently verify the utility of the Van Nuys prognostic index for ductal carcinoma in situ. Cancer. 2007; 10: 2648-2653. (Pubitemid 350250333)
13. Bijker N, Meijnen P, Peterse J, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006; 24: 3381-3387. (Pubitemid 46638893)
14. Silverstein M, Lagios M, Craig P, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996; 77: 2267-2274. (Pubitemid 26162419)
15. Silverstein M, Poller D, Waisman J, et al. Prognostic classification of breast ductal carcinoma-in situ. Lancet. 1995; 345: 1154-1157.
16. Cornfield D, Palazzo J, Schwartz G, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast. Cancer. 2004; 100: 2317-2327.
17. Tamimi RM, Baer HJ, Marotti J, et al. Molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008; 10: R67.
18. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007; 131: 18-43. (Pubitemid 46174133)
19. Schwartz GF, Solin LJ, Olivotto IA, et al. Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999. Cancer. 2000; 88: 946-954. (Pubitemid 30091115)
20. Sahoo S, Recant W, Jaskowiak N, et al. Defining negative margins in DCIS patients treated with breast conservation therapy: the University of Chicago experience. Breast J. 2005; 11: 242-247. (Pubitemid 41026037)
21. Cao D, Lin C, Woo S, et al. Separate cavity margin sampling at the time of initial breast lumpectomy significantly reduces the need for reexcisions. Am J Surg Pathol. 2005; 29: 1625-1631.
22. Dunne C, Burke J, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009; 27: 1615-1620.
23. Sigal-Zafrani B, Lewis J, Clough K, et al. Histological margin assessment for breast ductal carcinoma in situ: precision and implications. Mod Pathol. 2004; 17: 81-88. (Pubitemid 41656456)
24. Middleton, LP, Price JM, Puig P, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 guideline recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med. 2009; 133: 775-780.
25. Solin LJ, Yeh I, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation correlation of pathologic parameters with outcome of treatment. Cancer. 1993; 71: 2532-2542. (Pubitemid 23100488)
26. Ottesen GL, Graversen HP, Blichert-Toft M, et al. Ductal carcinoma in situ of the female breast: short term results of a prospective nationwide study: The Danish Breast Cancer Cooperative Group. Am J Surg Pathol. 1992; 16: 1183-1196. (Pubitemid 23004424)
27. Badve S, A'Hern RP, Ward AM, et al. Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. Hum Pathol. 1998; 29: 915-923. (Pubitemid 28422039)
28. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 232: 177-182. (Pubitemid 17231334)
29. Kepple J, Henry-Tillman, R, Klimberg VS, et al. The receptor expression pattern in ductal carcinoma in situ predicts recurrence. Am J Surg. 2006; 192: 68-71. (Pubitemid 43870050)
30. Kerlikowske, K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010; 102: 627-637.
31. Roses, RE, Paulson, EC, Sharma A, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1386-1389.
32. Reis-Filho JS, Tutt AN,. Triple negative tumours: a critical review. Histopathology. 2008; 52: 108-118. (Pubitemid 350265179)
33. Wiechmann, L, Kuerer, HM,. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 2008; 112: 2130-2142. (Pubitemid 351628621)
34. Czerniecki, BJ, Koski GK, Koldovsky U,. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007; 67: 1842-1852. (Pubitemid 46383411)